In vitro antitumor activity of 3'-desamino-3'(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 2, 1997, Pages 180-184

  Alvino, Ester ^a   Gilberti, Sara ^c   Cantagallo, Daniela ^c   Massoud, Renato ^c   Gatteschi, Antonietta ^c   Tentori, Lucio ^c   Bonmassar, Enzo ^b   D'Atri, Stefania ^b  

^a CNR   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Anthracyclines; Chemotherapy; Melanoma; Triazenes

Indexed keywords

DOXORUBICIN; DOXORUBICIN DERIVATIVE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; NEMORUBICIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MELANOMA; P-GLYCOPROTEIN; TRIAZENES; TUMOR CELLS, CULTURED;

EID: 0030946919     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050644     Document Type: Article

References (39)

1. Balch CM, Houghton AN, Peters LJ (1993) Cutaneous melanoma. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Philadelphia, p 1612
2. Bradford MM (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Ann Bioehem 72: 248
3. Chawla SP, Legha SS, Bengiman RS (1985) Detrorubicin an active anthracycline in untreated metastatic melanoma. J Clin Oncol 11: 1529
4. Danesi R, Agen C, Grandi M, Nardini V, Bevilacqua G, Del Tacca M (1993) 3′-Deamino-3′-(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity. Eur J Cancer 29A: 1560
5. 6-alkylguanine-DNA-alkyltransferase levels: studies with blasts of leukaemic patients. Ann Oncol 6: 389
6. Del Prete SA, Maurer LH, O'Donnel J, Forcier RJ, Le Marbre P (1984) Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep 68: 1403
7. Duran GE, Lau DHM, Lewis DA, Kuhl JS, Bammler TK, Sikic BI (1996) Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues. Cancer Chemother Pharmacol 38: 210
8. Foglesong PD, Reckord K, Swink S (1992) Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol 30: 123
9. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JRW, Hickson ID (1991) Relationship between topoisomerase II level and Chemosensitivity in human tumor cell lines. Cancer Res 51: 6592
10. Golub ASH, Hanson DC, Sulit HL, Morton D, Pellegrino MA, Ferrone S (1976) Comparison of histocompatibility antigens on cultured human tumor cells and fibroblasts by quantitative antibody absorption and sensitivity to cell-mediated cytotoxicity. J Natl Cancer Inst 56: 167
11. Graham MA, Riley RJ, Morrison LH, Plumb J, Fisher G, Kerr DJ, Workman P (1992) Methoxymorpholinyl-doxorubicin: elucidating a novel mechanism of metabolic activation involving cytochrome P450 3A. Ann Oncol 3: 186
12. Grandi M, Pezzoni G, Ballinari D, Capolongo L, Suarato A, Bargiotti A, Faiardi D, Spreafico F (1990) Novel anthracycline analogs. Cancer Treat Rev 17: 133
13. Grandi M, Mariani M, Ballinari D, Pezzoni G, Suarato A, Sprealico F, Chen M, Danks MK, Beck WT (1990) Lack of cross resistance to certain anthracycline analogs in human leukemic multidrug resistant cells (MDR) expressing either P-glycoprotein or altered DNA topoisomerase II. Proc Am Assoc Cancer Res 31: 357
14. Griffith OW (1985) Glutathione and glutathione disulfide. In: Bergmayer U (ed) Methods of enzymatic analysis. Academic Press, New York, p 521
15. Habig WH, Jakoby WB (1981) Assay for differentiation of glutathione S-transferase. In: Jakoby WB (ed) Methods in enxymology. Academic Press, New York, p 398
16. Kuhl JS, Duran GE, Chao NJ, Sikic BI (1993) Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal hone marrow. Cancer Chemother Pharmacol 33: 10
17. Lau DHM, Lewis AD, Duran GE, Sikic BI (1991) The cellular and biochemical pharmacology of the metoxy morpholino derivative of doxorubicin, FCE 23762 (abstract 1970). Proc Am Assoc Cancer Res 32: 332
18. Lau DHM, Duran GE, Lewis AD, Sikic BI (1994) Metabolic conversion of metoxymorpholinyl doxorubicin from a DNA strand breaker to a DNA cross-linker. Br J Cancer 70: 79
19. Lawrence RA, Burk RF (1976) Glutathione peroxidase activity in selenium deficient rat liver. Biochem Biophys Res Commun 71: 952
20. Lewis AD, Lau DHM, Duran GE, Wolf RC, Sikic BI (1992) Role of the cytochrome P450 from the human CYP 3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. Cancer Res 52: 4379
21. Lowry OH, Rosenbroug NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265
22. McClay EF, Hunger K (1991) Melanoma: new biology; new therapy CRC Crit Rev Oncol Hematol 11: 299
23. McClay EF, Mastrangelo MJ (1988) Systemic chemotherapy for malignant melanoma. Semin Oncol 15: 569
24. McClay EF, Mastrangelo MJ, Bellet RE, Berd D (1987) Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71: 465
25. Mimnaugh EG, Dusre L, Atwell J, Myers CE (1989) Differential oxygen radical susceptibility of Adriamycin-sensitive and -resistant MCF-7 human breast tumor cells. Cancer Res 49: 8
26. 6-alkylguanine alkyltransferase activity in Chinese hamster V79 cells following selection with chloroethylating agents. Carcinogenesis 9: 45
27. Nardelli B, Contessa AR, Romani L, Fava G, Nisi C (1984) Immunological changes of murine lymphoma cells following in vitro treatment with aryl-triazene derivatives. Cancer Immunol Immun 16: 157
28. 6-alkylguanine. FASEB J 6: 2302
29. Raghu G, Pierre-Jerome M, Dordal MS, Simonian P, Bauer KD, Winter JN (1993) P-glycoprotein and alterations in the glutathione/glutathione-peroxidase cycle underlie doxorubicin resistance in HL-60-R, a subclone of the HL-60 human leukemia cell line. Int J Cancer 53: 804
30. Ramachandran C, Samy TSA, Huang XL, Yuan ZK, Krishan A (1993) Doxorubicin-induced DNA breaks, topoisomerase II activity and gene expression in human melanoma cells. Biochem Pharmacol 45: 1367
31. Ripamonti M, Pezzoni G, Pesenti E, Pastori A, Farao M, Bargiotti A, Suarato A, Spreafico F, Grandi M (1992) In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumor cells. Br J Cancer 65: 703
32. Samuels BL, Murray JL, Cohen MB, Safa AR, Sinha BK, Townsend AJ, Beckett MA, Weichselbaum RR (1991) Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance. Cancer Res 51: 521
33. Tagliabue G, Pifferi A, Balconi G, Mascellani E, Geroni C, D'Incalci M, Ubezio P (1993) Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to DNA-interacting anti-neoplastic agents. Int J Cancer 54: 435
34. Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens RD, Richards MA (1991) Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother Pharmacol 28: 302
35. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 25: 1643
36. Van der Graaf WTA, Mulder NH, Meijer C, de Vries EGE (1995) The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts. Cancer Chemother Pharmacol 35: 345
37. Vasey PA, Bisset D, Strolin-Benedetti M, Poggesi I, Breda M, Adams L, Wilson P, Pacciarini MA, Kaye SB, Cassidy J (1995) Phase I clinical and pharmacokinetic study of 3′-deamino-3′-(2-methoxy-4-morpholinyl) doxorubicin (FCE 23762). Cancer Res 55: 2090
38. Wassermann K, Markovits J, Jaxel C, Capranico G, Kohn KW, Pommier Y (1990) Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerase I and II. Mol Pharmacol 38: 38
39. Waxman DJ (1990) Glutathione S-transferase: role in alkylating agent resistance and possible target for modulation chemotherapy review. Cancer Res 50: 6449